Nisa Investment Advisors LLC Purchases 45,060 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Nisa Investment Advisors LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 72.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 107,474 shares of the biotechnology company's stock after buying an additional 45,060 shares during the quarter. Nisa Investment Advisors LLC's holdings in Exelixis were worth $3,968,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC bought a new stake in shares of Exelixis during the fourth quarter worth $25,000. Colonial Trust Co SC lifted its holdings in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Exelixis during the first quarter worth $37,000. Crowley Wealth Management Inc. acquired a new position in shares of Exelixis during the fourth quarter worth $50,000. Finally, Hurley Capital LLC acquired a new position in shares of Exelixis during the fourth quarter worth $68,000. Institutional investors own 85.27% of the company's stock.

Insider Activity at Exelixis

In other news, Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the completion of the sale, the director directly owned 21,380 shares of the company's stock, valued at $913,781.20. The trade was a 46.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Amy C. Peterson sold 72,776 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the sale, the chief marketing officer directly owned 465,393 shares of the company's stock, valued at $21,161,419.71. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock valued at $21,024,817 over the last quarter. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded down $0.31 during trading on Friday, hitting $44.86. 2,063,340 shares of the company traded hands, compared to its average volume of 2,526,352. The business's fifty day moving average is $42.42 and its 200 day moving average is $38.06. Exelixis, Inc. has a fifty-two week low of $22.20 and a fifty-two week high of $49.62. The firm has a market capitalization of $12.23 billion, a price-to-earnings ratio of 20.39, a P/E/G ratio of 0.90 and a beta of 0.28.

Analyst Ratings Changes

A number of equities analysts have recently commented on EXEL shares. Truist Financial reiterated a "buy" rating and set a $55.00 price target (up previously from $43.00) on shares of Exelixis in a report on Monday, June 23rd. Bank of America lifted their price target on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday, June 5th. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, Benchmark restated a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $44.72.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.